S&P 500   5,124.77 (-1.43%)
DOW   37,996.12 (-1.20%)
QQQ   437.87 (-1.68%)
AAPL   175.20 (+0.09%)
MSFT   421.71 (-1.45%)
META   513.87 (-1.78%)
GOOGL   158.00 (-0.88%)
AMZN   185.59 (-1.83%)
TSLA   170.96 (-2.08%)
NVDA   885.55 (-2.27%)
AMD   162.80 (-4.52%)
NIO   4.09 (-8.30%)
BABA   71.98 (-3.83%)
T   16.36 (-0.37%)
F   12.62 (-3.22%)
MU   123.10 (-3.46%)
GE   154.09 (-2.10%)
CGC   7.96 (-2.33%)
DIS   114.18 (-2.54%)
AMC   2.70 (-3.57%)
PFE   26.01 (-1.25%)
PYPL   64.82 (-1.49%)
XOM   121.64 (-0.12%)
S&P 500   5,124.77 (-1.43%)
DOW   37,996.12 (-1.20%)
QQQ   437.87 (-1.68%)
AAPL   175.20 (+0.09%)
MSFT   421.71 (-1.45%)
META   513.87 (-1.78%)
GOOGL   158.00 (-0.88%)
AMZN   185.59 (-1.83%)
TSLA   170.96 (-2.08%)
NVDA   885.55 (-2.27%)
AMD   162.80 (-4.52%)
NIO   4.09 (-8.30%)
BABA   71.98 (-3.83%)
T   16.36 (-0.37%)
F   12.62 (-3.22%)
MU   123.10 (-3.46%)
GE   154.09 (-2.10%)
CGC   7.96 (-2.33%)
DIS   114.18 (-2.54%)
AMC   2.70 (-3.57%)
PFE   26.01 (-1.25%)
PYPL   64.82 (-1.49%)
XOM   121.64 (-0.12%)
S&P 500   5,124.77 (-1.43%)
DOW   37,996.12 (-1.20%)
QQQ   437.87 (-1.68%)
AAPL   175.20 (+0.09%)
MSFT   421.71 (-1.45%)
META   513.87 (-1.78%)
GOOGL   158.00 (-0.88%)
AMZN   185.59 (-1.83%)
TSLA   170.96 (-2.08%)
NVDA   885.55 (-2.27%)
AMD   162.80 (-4.52%)
NIO   4.09 (-8.30%)
BABA   71.98 (-3.83%)
T   16.36 (-0.37%)
F   12.62 (-3.22%)
MU   123.10 (-3.46%)
GE   154.09 (-2.10%)
CGC   7.96 (-2.33%)
DIS   114.18 (-2.54%)
AMC   2.70 (-3.57%)
PFE   26.01 (-1.25%)
PYPL   64.82 (-1.49%)
XOM   121.64 (-0.12%)
S&P 500   5,124.77 (-1.43%)
DOW   37,996.12 (-1.20%)
QQQ   437.87 (-1.68%)
AAPL   175.20 (+0.09%)
MSFT   421.71 (-1.45%)
META   513.87 (-1.78%)
GOOGL   158.00 (-0.88%)
AMZN   185.59 (-1.83%)
TSLA   170.96 (-2.08%)
NVDA   885.55 (-2.27%)
AMD   162.80 (-4.52%)
NIO   4.09 (-8.30%)
BABA   71.98 (-3.83%)
T   16.36 (-0.37%)
F   12.62 (-3.22%)
MU   123.10 (-3.46%)
GE   154.09 (-2.10%)
CGC   7.96 (-2.33%)
DIS   114.18 (-2.54%)
AMC   2.70 (-3.57%)
PFE   26.01 (-1.25%)
PYPL   64.82 (-1.49%)
XOM   121.64 (-0.12%)
NASDAQ:HOTH

Hoth Therapeutics (HOTH) Stock Price, News & Analysis

$1.22
-0.05 (-3.94%)
(As of 12:46 PM ET)
Today's Range
$1.22
$1.31
50-Day Range
$1.15
$1.65
52-Week Range
$0.99
$4.30
Volume
15,036 shs
Average Volume
438,157 shs
Market Capitalization
$5.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Hoth Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
205.3% Upside
$4.00 Price Target
Short Interest
Bearish
5.00% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.29mentions of Hoth Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.35 out of 5 stars

HOTH stock logo

About Hoth Therapeutics Stock (NASDAQ:HOTH)

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

HOTH Stock Price History

HOTH Stock News Headlines

Gold Hits New All-Time Highs
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
Gold Hits New All-Time Highs
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
See More Headlines
Receive HOTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hoth Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
4/12/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:HOTH
Fax
N/A
Employees
2
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$4.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+217.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-7,840,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.03 per share

Miscellaneous

Free Float
4,259,000
Market Cap
$5.55 million
Optionable
Not Optionable
Beta
0.63
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Robb Knie (Age 55)
    President, CEO & Chairman
    Comp: $844.01k
  • Mr. David S. Briones (Age 48)
    Chief Financial Officer
  • Ms. Hayley Springer
    Executive Vice President of Operations

HOTH Stock Analysis - Frequently Asked Questions

Should I buy or sell Hoth Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hoth Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" HOTH shares.
View HOTH analyst ratings
or view top-rated stocks.

What is Hoth Therapeutics' stock price target for 2024?

1 Wall Street analysts have issued 12 month price targets for Hoth Therapeutics' shares. Their HOTH share price targets range from $4.00 to $4.00. On average, they expect the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 205.3% from the stock's current price.
View analysts price targets for HOTH
or view top-rated stocks among Wall Street analysts.

How have HOTH shares performed in 2024?

Hoth Therapeutics' stock was trading at $1.44 at the start of the year. Since then, HOTH stock has decreased by 9.0% and is now trading at $1.31.
View the best growth stocks for 2024 here
.

Are investors shorting Hoth Therapeutics?

Hoth Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 218,100 shares, an increase of 698.9% from the March 15th total of 27,300 shares. Based on an average daily volume of 473,500 shares, the short-interest ratio is presently 0.5 days. Approximately 5.0% of the company's stock are short sold.
View Hoth Therapeutics' Short Interest
.

When is Hoth Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our HOTH earnings forecast
.

How were Hoth Therapeutics' earnings last quarter?

Hoth Therapeutics, Inc. (NASDAQ:HOTH) issued its earnings results on Wednesday, November, 10th. The company reported ($3.50) EPS for the quarter, missing the consensus estimate of ($3.38) by $0.13.

When did Hoth Therapeutics' stock split?

Shares of Hoth Therapeutics reverse split on Wednesday, October 26th 2022. The 1-25 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Hoth Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hoth Therapeutics investors own include Citius Pharmaceuticals (CTXR), Ocugen (OCGN), Fulcrum Therapeutics (FULC), Heat Biologics (HTBX), Tonix Pharmaceuticals (TNXP), AIM ImmunoTech (AIM), Aytu BioPharma (AYTU), Gilead Sciences (GILD), iBio (IBIO) and Nabriva Therapeutics (NBRV).

When did Hoth Therapeutics IPO?

Hoth Therapeutics (HOTH) raised $8 million in an IPO on Friday, February 15th 2019. The company issued 1,300,000 shares at a price of $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO.

How do I buy shares of Hoth Therapeutics?

Shares of HOTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HOTH) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners